Skip to content
Stories

Abortion Providers Gear Up for Judge’s Ruling Over Pill Approval

A recent Bloomberg Law article reports on an upcoming court ruling for the case Alliance for Hippocratic Medicine v. FDA, which will decide whether to halt production of mifepristone, an abortion pill. Professor Wendy Parmet, director of Northeastern University’s Center for Health Policy and Law, is quoted in the article. She asserts that “This would be an injunction that really changes the status quo. It’s a pretty momentous thing to take the medication off the market that had been on the market for 20 years.”This ruling will have significant implications for medical abortions in the United States— mifepristone is the most common form of abortion care, and its injunction would leave only two options, a misoprostol-only regimen, or surgical abortion. Attorneys note that if the judge rules to immediately remove the drug from the marketplace, the case could its way to the Supreme Court.

This would be an injunction that really changes the status quo. It’s a pretty momentous thing to take the medication off the market that had been on the market for 20 years.

Wendy Parmet, Northeastern University Center for Health Policy and Law

Read more on the potential implications for the ruling at Bloomberg Law.
Image credits: Bloomberg Law

More Stories

New I.V.F Supreme Court of Alabama ruling shows only the beginning of the fight over fertility treatment.

03.18.2024

Abortion pills become accessible at pharmacy chains CVS and Walgreens in select locations.

03.18.2024

Abortion Case Could Limit Accessibility of Medication and Harm The Future Of Reproductive Health

04.03.24
News